 By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Licenses Two Assets for Potentially Treating COVID-19 On April 20, 2020, Edesa Biotech, Inc. NASDAQ:EDSA announced an exclusive licensing agreement with Light Chain Bioscience for two clinical-stage monoclonal antibody assets targeting toll-like receptor 4 TLR4 and C-X-C motif chemokine 10 CXCL10. Light Chain 